Skip to content

Hypothalamic Amenorrhea as a Fertility Status Marker for Cardiovascular Health (ARCH)

Hypothalamic Amenorrhea as a Fertility Status Marker for Cardiovascular Health

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05629377
Acronym
ARCH
Enrollment
90
Registered
2022-11-29
Start date
2023-01-17
Completion date
2026-12-01
Last updated
2026-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypothalamic Amenorrhea

Keywords

Functional Hypothalamic Amenorrhea, Amenorrhea

Brief summary

Hypothalamic amenorrhea (HA) occurs during reproductive years and results in stopped menstrual cycles and infertility which can be prolonged from months to years and is characterized by varying combinations of psychosocial stress, anxiety, high levels of physical activity, and/or weight loss. Data from our group indicates that one-third of women with HA (mean age: 27 yrs) have preclinical cardiovascular disease (CVD) measured noninvasively as vascular dysfunction and vascular inflammation. This study will use HA as a marker of fertility status for cardiovascular health and perform dense-phenotyping using remote patient monitoring (FitBit) and patient reported outcomes (questionnaires) to determine which HA phenotypes are related to preclinical CVD and inflammation.

Interventions

None listed

Sponsors

Mayo Clinic
Lead SponsorOTHER
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
CollaboratorNIH

Study design

Observational model
COHORT
Time perspective
OTHER

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 40 Years
Healthy volunteers
No

Inclusion criteria

* Secondary amenorrhea of 3 or more consecutive months duration * Include the screening hormones (eg, estradiol (E2) \< 50 pg/ml, Follicle-Stimulating Hormone (FSH) \<10 mIU/ml, and Luteinizing Hormone (LH) \< 10mIU/ml and other HA-defining hormones); or clinical diagnosis of HA by medical providers. * Pre-menopause status. * Able to give informed consent.

Exclusion criteria

* A diagnosis for secondary amenorrhea including prolactinoma, Polycystic Ovary Syndrome (PCOS), premature ovarian insufficiency, pituitary surgery, infection or infarction * Pregnancy * Psychotropic/illicit drug use * Mental/neurological/major psychological disorders (other than depression and anxiety). * Parturition/lactating in the last 6-12 months.

Design outcomes

Primary

MeasureTime frameDescription
Hypothalamic Amenorrhea (HA) duration3 monthsDuration of HA by month of amenorrhea (absence of menstruation)
Vascular dysfunction3 monthsMeasured by reactive hyperemic index (RHI)
Psychosocial stress3 monthsMeasured by NIH PROMIS® short-form questionnaires
Perceived stress3 monthsMeasured by the validate perceived stress scale questionnaire, a 10-item questionnaire, scores range from 0 to 40; higher scores indicate higher levels of perceived stress.
Step count3 monthsMeasured by Fitbit Versa 2 watch that tracks steps per day, active and resting heart rate, sleep hours per day
Physical activity level3 monthsMeasured by Fitbit Versa 2 watch that tracks amount of light physical activity, moderate, and vigorous activity
Heart Rate3 monthsMeasured by Fitbit Versa 2 watch that tracks heart rate
Caloric intake and nutrition3 daysMeasured using a self-reported food diary
Vascular inflammation3 monthsconcentration of cytokines multiplex immunoassay platform

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORChrisandra Shufelt, MD

Mayo Clinic

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 5, 2026